^
Association details:
| Biomarker: | PMS2 mutation + MLH1 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.
Published date:
05/25/2023
Excerpt:
...loss of expression of MLH1 and PMS2 (MutL co-loss). Here, we expanded our analysis and included gastrointestinal (GI) non-CRCs and explored the impact of dual vs. monotherapy ICIs on mOS in GI (CRC and non-CRC) cancers….In ICI-treated GI (CRC and non-CRC) patients with MutL co-loss, there was a trend for better survival with ipi/nivo compared to pembro.
DOI:
10.1200/JCO.2023.41.16_suppl.2620
